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Intrypanosomatids,glucose-6-phosphatedehydrogenase (G6PDH),theﬁrstenzymeofthepentosephosphatepathway,isessential
forthe defense ofthe parasite againstoxidative stress. Trypanosoma brucei, Trypanosoma cruzi,a n dLeishmania mexicana G6PDHs
have been characterized. The parasites’ G6PDHs contain a unique 37 amino acid long N-terminal extension that in T. cruzi seems
to regulate the enzyme activity in a redox-state-dependent manner. T. brucei and T. cruzi G6PDHs, but not their Leishmania spp.
counterpart, areinhibited, inanuncompetitive way,by steroidssuch asdehydroepiandrosterone andderivatives. TheTrypanosoma
enzymesare moresusceptible to inhibitionby thesecompounds thanthehumanG6PDH. The steroids alsoeﬀectively kill cultured
trypanosomes but not Leishmania and are presently considered as promising leads for the development of new parasite-selective
chemotherapeutic agents.
1.Introduction
The family Trypanosomatidae, belonging to the order Kine-
toplastida, contains a large number of species, distributed
over several genera. All known members of the Trypanoso-
matidae family are parasites, infectious to humans and other
mammals, other vertebrates, insects and plants. The human-
infective trypanosomatids are grouped in species of two
genera, Trypanosoma and Leishmania. They are responsible
for a wide spectrum of diseases in tropical and subtropical
countries.Two subspeciesofTrypanosomabrucei,T. b. rhode-
siense,a n dT. b. gambiense, are responsible for diﬀerentforms
of Human African Trypanosomiasis or sleeping sickness, an
endemic disease in over 250 distinct foci in rural areas of
36 sub-Saharan African countries. The currently estimated
number of cases is 50,000–70,000with 17,000new infections
annually and 60 million people at risk [1, 2]. The parasite is
transmitted between human and/or other mammalian hosts
by the tsetse ﬂy. The complex life cycle of this extracellular
parasite includes a procyclic form present in the midgut of
the insect vector and a bloodstream form present in the
blood of the mammalian hosts [3].
Trypanosoma cruzi is responsible for Chagas’ disease in
most countries of Latin America. It is estimated that 11–
18 million people are infected; 13,000 deaths are reported
annually and about 100 million people are at risk [4]. The
parasites are transmitted by blood-sucking reduviid bugs.
After infection, the metacyclic trypomastigotes invade host
cells where they proliferate as the so-called amastigote forms
and, after diﬀerentiation into bloodstream trypomastigotes,
they infect more cells, notably of heart muscle, and alimen-
tary track tissue [1, 5, 6].
Diﬀerent species of Leishmania cause a variety of clinical
symptoms, collectively called Leishmaniases. These diseases2 Molecular Biology International
may involve cutaneous and mucocutaneous lesions, often
causing severe debilitating wounds, or life-threatening vis-
ceral diseases in which vital organs are aﬀected. The diseases
threaten about 350 million people in 88 countries in tropical
and subtropical parts of the world. An estimated 12 million
people are currently infected with about 1-2 million new
casesoccurringannually.Leishmania transmission occursvia
the byte of sandﬂies which inject metacyclic promastigote
parasites into the skin. These forms enter macrophages
where they reside as multiplying amastigotes within the
phagolysosomes [7].
Sleepingsickness, Chagas’disease and visceral leishmani-
asis can have a fatality rate as high as 100% if left untreated
or not treated properly [1, 8]. But treatment with drugs
currently available is highly unsatisfactory [9, 10]. Most
drugs have low eﬃcacy and adverse side eﬀects. Moreover
the emergence of drug resistance is a continuous concern.
Therefore, and because of the lack of eﬃcacious vaccines,
the discovery and development of eﬀective drugs, nontoxic,
aﬀordable and easy to administer to the aﬀected populations
in the resource-poor areas is an urgent need.
Despite the tremendous progress made in recent decades
in understanding the biochemistry and molecular biology of
trypanosomatid parasites [11–14], chemotherapeutic treat-
ment of the diseases has seen limited progress.
A currently common strategy for drug discovery against
any parasitic diseases is to identify essential metabolic
pathways associated with the parasites. In trypanosomatids,
several enzymes involved in various metabolic processes
have been characterized and established as promising drug
targets [14, 15]. Among these validated targets is glucose-
6-phosphate dehydrogenase (G6PDH; EC 1.1.1.49), a key
enzyme of the pentosephosphate pathway.
2.The Roleofthe PentosephosphatePathway
and Glucose-6-PhosphateDehydrogenase
Inmostorganismsglucoseismetabolizedthroughtwomajor
pathways: the glycolytic and the pentosephosphate pathway
(PPP) [16]. Whereas glycolysis serves for ATP production
and to produce metabolites for use in a large variety of
anabolic or further catabolic processes, the PPP can be
dividedintwosuccessivephaseswithdiﬀerentfunctions.The
ﬁrstphase,calledoxidativebranch,generatesreducingpower
under the form of NADPH and the second one, also known
as nonoxidative or sugar interconversion branch, involves a
series ofreversiblenonoxidative reactions leading to the con-
version of the 5-carbon sugar resulting from the ﬁrst phase
into othermetabolites(Figure 1). The oxidative branch com-
prises three enzymes: G6PDH, 6-phosphogluconolactonase,
and 6-phosphogluconate dehydrogenase (6PGDH), whose
successive activities convert glucose 6-phosphate (G6P) into
ribulose 5-phosphate, with the concomitant production of
NADPH by both dehydrogenases and CO2 release by the
decarboxylation of the 6-phosphogluconateby 6PGDH [17].
The NADPH is used by the cell as a reducing agent in a
variety of biosynthetic processes as well as for the defense
against reactive oxygen species by keeping glutathione in its
reduced state [18]. Glutathione is the major endogenous cel-
lular antioxidant, participating directly in the neutralization
of free radicals and reactive oxygen compounds, as well as
maintaining exogenous antioxidants such as vitamins C and
E in their reduced, active forms.
T h en o n o x i d a t i v eb r a n c hc o m p r i s e sr i b o s e - 5 - p h o s p h a t e
isomerase, ribulose-5-phosphate epimerase, transketolase
and transaldolase, which, by isomerase and epimerase reac-
tions and the transfer of two- and three-carbon units, form
a variety of intermediates including ribose 5-phosphate,
required for nucleotidesynthesis, and erythrose 4-phosphate
a precursor of aromatic amino acids and vitamins [19].
D e p e n d i n go nt h ec e l l ’ sn e e d s ,t h eP P Pc a nf u n c t i o n
partially or as a whole cycle by which one of the possible
products, fructose 6-phosphate, is converted back into G6P,
to enter the oxidative branch again. In addition, the PPP and
glycolytic pathway are connected by sharing some interme-
diates such as G6P, fructose 6-phosphate and glyceraldehyde
3-phosphate.
G6PDH is the ﬁrst committed enzyme of the PPP.
Although most organisms have other means to produce
cellular NADPH,notably by the enzymes isocitrate dehydro-
genase and malic enzyme, the generally important role of
G6PDH in it is illustrated by the severity of G6PDH deﬁ-
ciency in humans. The deﬁciency may lead to nonimmune
hemolytic anemia triggered by oxidative stress as a result
of infections or exposure to chemicals such as present in
medication or certain foods [20]. G6PDH deﬁciency is the
most common human enzyme defect, occurring in more
than 400 million people worldwide [21].
3.Glucose-6-PhosphateDehydrogenase in
Trypanosomatids
The presence of G6PDH activity in trypanosomatids was
ﬁrst demonstrated in 1959 by Raw in T. cruzi epimastigotes
[22] and in 1962 by Ryley in both cultured procyclic and
bloodstream form T. b. rhodesiense [23]. A few years later,
studies with labeled glucose by Mancilla and colleagues
[24–26] suggested that the PPP is functional in some T. cruzi
strains and Leishmania speciesand, much later, Voorheis and
coworkers[27]conﬁrmedthepresenceofaclassicalPPPinT.
brucei by determining the speciﬁc activities of all its enzymes
in both procyclic and bloodstream forms. Interestingly, no
activities of ribulose-5-phosphate epimerase and transketo-
lase were detectable in the bloodstream form and only low
activity was found fortransaldolase, suggesting an important
diﬀerential repression of the nonoxidative branch in thislife-
cycle stage [27]. For some of the PPP enzymes, like G6PDH
and 6-phosphogluconolactonase, a dual subcellular distri-
bution was later found in both bloodstream and procyclic
form trypanosomes. While their main enzymatic activity
was present in the cytosol, approximately 40 and 10%,
respectively, of their activity was associated with glycosomes
[28, 29]. Glycosomes are the peroxisome-like organelles in
Kinetoplastida which uniquely harbour the majority of the
enzymes of the glycolytic pathway [30]. These organelles,Molecular Biology International 3
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Figure 1: Schematic representation of the pentosephosphate pathway.
which number between 5 and 10 in Leishmania amastigotes
and approximately 65 in bloodstream form T. brucei,m a y
contain enzymes from a variety of diﬀerent pathways [31–
33], with the glycolytic enzymes being most notable and
comprisingevenupto90%oftheorganelles’ proteincontent
as observed in bloodstream form trypanosomes [33–35].
A functional PPP has also been unambiguously demon-
strated in T. cruzi epimastigotes by measuring the CO2
production from radiolabeled glucose [36]. Moreover, the
importance ofthe PPP wasdemonstrated by achallenge with
methylene blue, mimicking oxidative stress, which caused a
twofold increase of the ﬂux through the PPP. All enzymes
of the pathway were identiﬁed by activity measurements in
the four major developmental stages of this parasite. The
activities were shown to be predominantly cytosolic, with a
possible small glycosomal component for most of them.4 Molecular Biology International
Table 1: T. brucei (Tb),T. cruzi (Tc),andL. mexicana (Lm) G6PDH kinetic constants for an ordered bi-bi-reaction mechanism.
Source KG6P KNADP+ V1 kcat KiG6P
(μM) (μM) (nmoles of NADPH·s−1)( s −1)( μM)
Tb 57.8 ± 2.4 9.4 ± 0.4 36.2 ± 1.5 16.4 ± 0.6 47.6 ± 1.9
Tc 206.0 ± 4.2 22.5 ± 1.2 77.7 ± 2.5 57.1 ± 1.9 105.3 ± 4.6
Lm 74.5 ± 3.0 12.1 ± 0.5 31.2 ± 1.2 22.2 ± 0.9 86.4 ± 3.5
Data from Cordeiro et al. [45, 46].
In a comparable study, the presence of a functional
PPP was also demonstrated in promastigotes of Leishmania
mexicana, by its twofold stimulation by methylene blue.
Each of the classical PPP enzymes was identiﬁed and its
speciﬁc activity measured [37]. Furthermore, it was shown
that glucose serves as a source for nucleic acid synthesis,
an indication that, in these parasites, the PPP plays also a
role in the conversion of glucose into ribose 5-phosphate
for nucleotide biosynthesis. Also in Leishmania, the PPP
has probably a dual subcellular localization, although it has
only been demonstrated so far for the transketolase that
is predominantly present in the cytosol of promastigotes,
but also with a signiﬁcant component associated with the
glycosomes [38]. The presence of the PPP in glycosomes of
the three trypanosomatid species is further supported by
the presence of peroxisomal-targeting signals (PTSs) in a
number of enzymes of both the oxidative and nonoxidative
branches [31, 39]a n d — f o rT. brucei—by the results of
proteomic analyses [31, 32].
Whereas in almost all organisms, glutathione,reducedby
NADPH produced predominantly in the PPP, is the major
intermediateinthedefenseagainst reactiveoxygenspecies,in
trypanosomatids a diﬀerent thiol redox component is being
used, trypanothione, or N1,N8-bis-gluthionyl-spermidine.
Several enzymes involved in trypanothione metabolism have
been detected both in the cytosol and glycosomes [31].
Preliminary enzymatic studies on G6PDH have been
performed with the partially puriﬁed enzyme from T. cruzi
[40, 41]a n dT. brucei [28], but detailed characterization of
G6PDH of each of the three trypanosomatid species was
only performed after the genes had been identiﬁed and
used to producethe recombinant proteins. Genomic analysis
revealed one gene copy per haploid genome in T. brucei
[29]a n dL. mexicana [42] and several genes located on
three diﬀerent chromosomes of T. cruzi clone CL Brener
[43, 44]. Two of them were classiﬁed as pseudogenes, while
the others were clustered in three groups of nearly iden-
tical (98%) coding regions but with considerably diﬀerent
noncoding ﬂanking sequences. The amino acid sequences of
the functional G6PDHs of three trypanosomatids are 64 to
69% identical and share about 50% identity with the human
enzyme.
The T. brucei and T. cruzi G6PDH gene sequences both
have two possible start codons, 111bp apart (Figure 2),
while in Leishmania species only a unique start codon was
found corresponding to the ﬁrst one of the Trypanosoma
genes. The region between the two start codons codes for
a usual 37 amino acid N-terminal extension only present
in the trypanosomatid G6PDHs. The long form of the T.
brucei and T. cruzi enzymes code for polypeptides of 557
and 555 residues, respectively, while the L. mexicana G6PDH
polypeptideencompasses562residues.Westernblotanalysis,
performed with an antiserum raised against the N-terminal
peptide of the T. cruzi G6PDH, showed that mainly the long
form of the enzyme is expressed in all four life-cycle stages of
thisparasite [43].WhetherthelongformofT. brucei G6PDH
is also produced remains to be determined. Duﬃeux and
coworkers [29] proposed that an ORF starting at the ﬁrst
ATG codon would lead to an mRNA with an unusually short
5  untranslated region.
The L. mexicana G6PDH, the short form of the T.
brucei enzyme and both the long and short form of T.
cruzi G6PDH have been expressed with an N-terminal His-
tag in Escherichia coli, puriﬁed and kinetically characterized
[29, 43, 45, 46]. The kinetic mechanism has been studied,
under conditions which were similar for all enzymes, and
appeared to follow for each of them a bi-bi-ordered pattern
[45, 46]. The values of the kinetic constants are presented in
Table 1.
Interestingly, it was shown that the long and short
form of T. cruzi G6PDH present several diﬀerences [43].
Experiments performed independently from those for which
theresultsarepresentedinTable1,r ev ealeddiﬀerencesinthe
apparent Km values for G6P. While the puriﬁed recombinant
long and short T. cruzi G6PDH had apparent Km values of
189.9 and 98.4μM, respectively, that of the partially puriﬁed
enzyme from parasites was 288μM. In contrast, the apparent
Km values for NADP+ did not diﬀer. Additionally, both the
natural enzyme and the long recombinant G6PDH, but not
the short form, were inactivated by reducing agents such as
dithiothreitol, β-mercaptoethanol, and reduced glutathione.
This eﬀect,reminiscent tothe redox-state-dependentactivity
regulation observed for G6PDH and some other enzymes
from chloroplasts and cyanobacteria [47], was attributed to
the presence of two Cys residues in the N-terminal peptide
[43]. The corresponding N-terminal region of G6PDH of
Leishmania spp. and the possible extension of the T. brucei
enzyme do not contain these Cys residues (Figure 2).
These observations suggest that among the trypanosomatid
G6PDHs studied, only the activity of the T. cruzi enzyme
is regulated by the redox state of the cell, in a similar
way as reported for the enzyme from chloroplasts and
cyanobacteria. Indeed, kinetic studies with the two puriﬁed
recombinant forms showed that the long form was 4-fold
more sensitive for inhibition by the product NAPDH than
the short one, suggesting that its activity is regulated byMolecular Biology International 5
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Figure 2: G6PDH amino acid sequence alignment. The predicted amino acid sequences of T. cruzi G6PDH-long (DQ408239, sharing the
highestidentity with its T. brucei counterpart), T. brucei G6PDH-long (CAC07816),L. mexicana G6PDH (AAO37825),and Human G6PDH
(AAL27011) were aligned using the CLUSTALW software. The ﬁrst and second candidate initiator methionines in the T. cruzi and T. brucei
sequences are indicated with arrows. The two regulatory cysteines of the T. cruzi G6PDH are boxed in yellow. Overlined, cofactor binding
site; §G6PDH signature (residues belonging to the substrate binding site); #residues involved in substrate and cofactor binding.
the NADP+/NADPH ratio in the cell compartment where
the enzyme is located, similarly as has been proposed for the
enzyme from Anacystis nidulans [48].
The importance of G6PDH in the defense against
oxidative stress has been demonstrated for both the T. cruzi
[43]a n dT. brucei enzyme (SG and PM, unpublished; see
below). Incubation of T. cruzi with H2O2 modiﬁed the
G6PDH expression and speciﬁc activity in the cell (Figure 3).
In metacyclic trypomastigotes, the life-cycle stage naturally
exposed to reactive oxygen species (ROS) produced by
the mammalian host, the peroxide exposure enhanced the
G6PDH expression as well as the speciﬁc activity of the6 Molecular Biology International
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Figure 3: T. cruzi G6PDH expression and speciﬁc activity are
enhanced by oxidative stress in metacyclic trypomastigotes. Para-
sites were incubated for 4 to 6h in the presence of 70μMH 2O2.
Samples for enzymatic activity measurements and western blots
were taken before (T0) and after the H2O2 addition. (a) G6PDH
speciﬁc activity. The results are means ± SE of quadruplicates.
(b) Autoradiography of a western blot corresponding to metacyclic
trypomastigotes cell-free extracts (30μg of total protein/lane). α-
Tubulin wasused as loadingcontrol.(Figure created withdata from
[43].)
enzyme. Conversely, peroxide treatment in epimastigotes,
a life-cycle stage not naturally encountering such a host
response, repressed the G6PDH expression and activity. In
bloodstream forms of T. brucei G6PDH expression has been
knocked down by tetracycline-inducible RNA interference
(RNAi) [45]. Cells partially depleted from G6PDH showed
enhanced sensitivity to diﬀerent concentrations of H2O2
compared to wild-type trypanosomes (Figure 4).
4.Glucose-6-PhosphateDehydrogenase Is
a GeneticallyValidatedDrug
TargetinBloodstreamForm T. brucei
As stated before, most organisms can produce NADPH not
only by the action of the two dehydrogenases of the PPP—
G6PDH and 6PGDH—but also via isocitrate dehydrogenase
and malate dehydrogenase to copewith G6PDH deﬁciencies.
However, trypanosomatids depend only upon malic enzyme
[49] and G6PDH for their cytosolic NADPH production.
In these parasites the isocitrate dehydrogenase is compart-
mentalized inside the mitochondrion and, in species of
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Figure 4: G6PDH is important for defense against oxidative stress
in bloodstream form T. brucei. Wild-type (WT) trypanosomes
and cells in which partial depletion of G6PDH was induced by
RNAi were grown in regular HMI-9 medium. After growth for
diﬀerent periods of time as indicated, cells were collected by
centrifugation and resuspended in non-reducing medium (i.e.,
without β-mercaptoethanol and cysteine) and the cell density was
determined. Cell suspensions were then incubated for 1.5h in the
presence of diﬀerent concentrations of H2O2 after which the cell
density was determined again.
Trypanosoma but not Leishmania, it has also been predicted
as a glycosomal enzyme [39].
Asmentionedabove,T. brucei bloodstreamformG6PDH
RNAi cell lines have been created [45]. To determine if
inhibition of G6PDH (and consequently the ﬂux through
the downstream located PPP enzyme 6PGDH) was suﬃcient
to aﬀect the trypanosome growth, a cell line in which RNAi
induction led to a considerable reduction in G6PDH expres-
sion was studied. In these cells 24h of RNAi induction led to
amilddecreaseinG6PDH,while48hofknockdowninduced
a substantial reduction in G6PDH protein, as determined by
westernblotanalysis.ThedecreaseinG6PDHexpressionwas
paralleled by an impairment in the trypanosomes’ growth
rate. This eﬀect was observed between 24 and 48h after
the addition of tetracycline to the culture medium. Beyond
48h of RNAi induction, G6PDH depleted cells started to
die (Figure 5). Parasites containing the RNAi construct,
but grown in the absence of tetracycline, showed a similar
growth rate as wild-type cells grown in the presence or
absence of tetracycline. The decrease of the growth rate
correlated with the initiation of the RNAi induction and a
simultaneous decrease in the protein level, suggesting that
G6PDH plays an important role in growth and survival of
the bloodstream form trypanosomes. The possibility that
the observed phenotype was a consequence of an RNAi-oﬀ-
target eﬀe c tc a n n o tb ee x c l u d e d ,b u ti tw a sc o n s i d e r e dt ob e
unlikely since the G6PDH sequence is unique and no other
highly similar gene was identiﬁed in the T. brucei genome
database.Molecular Biology International 7
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Figure 5: Genetic validation of G6PDH as a drug target in
bloodstream form T. brucei. Cumulative growth of wild-type (WT)
trypanosomes and two independent cell lines (RNAiG6PDH A
and B). In the absence of RNAi induction (−Tet), WT and
RNAi parasites grow at equal rates; in the presence of the RNAi
inducer tetracycline (+Tet), WT cells grow at a normal rate, while
trypanosomes of the RNAi-cell lines die after 48h. (Figure created
with data from [45].)
These RNAiexperiments genetically validated G6PDH as
adrugtarget in bloodstream forms ofT. brucei and suggested
thatthe NADPHproducedbyotherenzymes thanG6PDH is
notsuﬃcienttodealwithoxidativestress experiencedduring
normal or stress conditions (Figure 4).
5.InhibitionofTrypanosomatid
G6PDH by Steroids
Inhibition of mammalian G6PDH by intermediates of the
steroid-hormones biosynthesis was discovered 50 years ago
byMark andBanks[50].Theydemonstratedahighlyspeciﬁc
and uncompetitive inhibitory eﬀect of dehydroepiandros-
terone (DHEA) and derivatives on human G6PDH. These
steroid molecules did not inhibit the homologous enzyme
of either yeast or spinach. Moreover they did not aﬀect
the activity of mammalian 6PGDH and isocitrate dehydro-
genase. During the following 35 years, it was a generally
accepted notion that only G6PDH from mammalian cells
was inhibited by steroid hormone derivatives [51]. As a
consequence of such a generalization, the inhibition of
G6PDH from lower eukaryotes, like trypanosomatids and
other human parasites, was neglected. Observations that
DHEA or derivatives of it were eﬀective against infections
of Cryptosporidium parvum [52], Plasmodium species [53],
Schistosoma mansoni [54], and T. cruzi [55] were attributed
to a stimulation of the host’s immune response by the
steroids. Nonetheless, in recent years it was shown that
the steroids also aﬀect growth of cultured parasites such
as Entamoeba histolytica [56]a n dTaenia crassiceps [57],
suggesting that they could have a direct eﬀect on these
organisms.
Recently, Cordeiro et al. [45] conﬁrmed these ﬁndings
by showing that steroids kill in vitro grown T. brucei blood-
stream forms with ED50 values in the micromolar range.
They additionally demonstrated that T. brucei G6PDH, the
ﬁrst nonmammalian enzyme, was eﬀectively inhibited by
DHEA and epiandrosterone (EA). Similar observations were
subsequently made for T. cruzi G6PDH [46]. Although,
DHEA itself failed to decrease the growth rate of cultured
T. cruzi, its brominated derivatives 16BrDHEA and 16BrEA
(Figure 6), which are more potent inhibitors of G6PDHs,
presented ED50 values in the micromolar range, comparable
to values reported for benznidazole [58], the currently avail-
able drug in use for treatment of Chagas’ disease. Curiously,
DHEA and EA did not inhibit L. mexicana G6PDH and
had no eﬀect on the growth rate of cultured promastigote
parasites. This observation was indirect evidence for the
speciﬁc inhibition of G6PDH by DHEA in trypanosomes.
6.G6PDH Isthe In Situ Target of Human
SteroidswithTrypanocidal Action
Recently, the mechanism by which DHEA and EA kill T.
brucei bloodstream forms has been evaluated, by exploiting
thefact thatthesecompoundsshowednoinhibitoryeﬀecton
the recombinant L. mexicana G6PDH. Inhibitors were tested
on the cell growth of a trypanosome clone that has been
created to also express a transgene encoding this L. mexicana
enzyme [59]. Whereas wild-type bloodstream form T. brucei
showed a dose-dependent killing by DHEA and EA with
ED50 valuesof41.8 ±2.1μM and21.4 ±1.6μM,respectively,
the T. brucei (LmG6PDH) transgenic parasites showed no
growth inhibition whatsoever by the two compounds, even
at concentrations up to 100μM[ 59]. Thus, transfection of
T. brucei bloodstream form parasites with LmG6PDH could
rescue the trypanosomes from being killed by DHEA and
EA. This result conﬁrms that the toxic eﬀect of DHEA and
EA on the parasites is uniquely due to the inhibition of their
G6PDH.
7.ConclusionsandPerspectives
Our research has validated the key PPP enzyme G6PDH
as a target for new drugs to be developed against try-
panosomes. Oxidative insults induce G6PDH expression
and enhance its speciﬁc activity, while the partial depletion
of this enzyme by RNAi makes the parasites vulnerable
to oxidative stress. Prolonged depletion of G6PDH from
cultured bloodstream form T. brucei resulted even in death
of the parasites. Whether this was only due to an eﬀect on
the redox metabolism or also on the synthesis of metabolic
intermediatestobeusedforbiosyntheticprocessesstill needs
to be addressed.8 Molecular Biology International
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Figure 6: Steroid inhibitors of Trypanosoma G6PDH. Two modiﬁcations used to increase the inhibitory potency of steroids to G6PDH are
indicated: reduction of the double bond between carbons 5 and 6 in dehydroepiandrosterone (DHEA) which leads to epiandrosterone (EA)
and the bromination at position 16 which converts DHEA and EA into 16BrDHEA and 16BrEA, respectively.
Steroids derived from DHEA are potent uncompetitive
inhibitors of Trypanosoma G6PDH, and indeed kill the para-
sites by in situ inactivating this enzyme. The uncompetitive
nature of this inhibition is particularly relevant. Contrary
to the much more often observed competitive inhibition,
the increase of substrate concentration, resulting from this
process, will not overcome the inhibition but may rather
lead to an increase of metabolic intermediates to toxic
levels [60]. The molecular mechanism by which the steroids
inhibit the G6PDH of human, Trypanosoma and other
lower eukaryotes including several human parasites, while
they do not aﬀect the activity of the enzyme from plants,
yeasts, and Leishmania is not yet known. To analyze the
diﬀerences between the Trypanosoma and human G6PDH’s
steroid binding site and the binding mechanism of these
molecules, cocrystallizationofthe enzymes with steroidsand
the determination of their crystal structure is needed. To
date, no three-dimensional structure of a trypanosomatid
G6PDH is available, but crystallization studies are presently
ongoingand,when successful, mayopennewpossibilitiesfor
the design and synthesis of a diﬀerentclass ofmolecules with
evenhigherinhibitorypotencyandselectivityfortheparasite
G6PDH.
Since these steroids inhibit Trypanosoma G6PDHs at
much lower concentrations than the mammalian G6PDH,
they are promising leads for the development of new drugs
for treatment of African sleeping sickness and Chagas’
disease.Thenextstepsinthedevelopmentofdrugcandidates
againstthesediseaseswillinvolvetheselectionofcompounds
with potent and highly selective inhibitory activity on
cultured parasites versus human cells, and the evaluation of
their eﬃcacy, bioavailability, and toxicity in infected animal
models.
The lack of inhibition of the Leishmania G6PDH by
DHEA and its derivatives is puzzling. It is feasible that this
is due to a single but crucial substitution in the enzyme that
prevents the binding of these compounds. Screening of a
steroid library against the available recombinant L. mexicana
G6PDHmayhelptoidentifypotentuncompetitiveinhibitors
with in vitro anti-Leishmania spp. activity.
Asmentionedabove,steroidsalsoimpaired thegrowthof
other parasites, that is, Taenia crassiceps and Entamoeba his-
tolytica,aswell astheparasitaemia ofPlasmodium falciparum
and P. berghei, Cryptosporidium parvum,a n dSchistosoma
mansoni. It is still necessary to determine if G6PDH is also
in these cases the main target of the steroid molecules. This
will opennewperspectivesfordiscovery ofdrugsalso against
the diseases caused by these parasites.
Concerning the trypanosomatid-borne diseases, the
availability of recombinant G6PDH for each of the three
parasites makes also possible an alternative strategy, that is,
using these enzymes for high-throughput screening of large
libraries of drug-like compounds. This approach may lead
to very wide range of inhibitors potentially exploitable for
antiparasitic treatment.
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